Morbidity after long-term remission for acromegaly: Persisting joint-related complaints cause reduced quality of life

Journal of Clinical Endocrinology and Metabolism

Volumn 90, Issue 5, 2005, Pages 2731-2739

  Biermasz, Nienke R ^a   Pereira, Alberto M ^a   Smit, Jan W A ^a   Romijn, Johannes A ^a   Roelfsema, Ferdinand ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; LONG ACTING DRUG; OCTREOTIDE; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; ADULT; ANXIETY; ARTICLE; BONE DISEASE; COMORBIDITY; DEPRESSION; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE DURATION; FATIGUE; FEMALE; HEART INFARCTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RATING SCALE; REMISSION; SCORING SYSTEM; SELF REPORT; SLEEP; TRANSSPHENOIDAL SURGERY;

ACROMEGALY; ADULT; AGED; DIABETES MELLITUS; FEMALE; HUMANS; HYPERTENSION; JOINT DISEASES; MALE; MIDDLE AGED; MORBIDITY; OSTEOARTHRITIS; PREVALENCE; QUALITY OF LIFE;

EID: 18844370346     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2004-2297     Document Type: Article

References (52)

1. Ben Shlomo A, Melmed S 2001 Acromegaly. Endocrinol Metab Clin North Am 30:565-583, vi
2. Nabarro JD 1987 Acromegaly. Clin Endocrinol (Oxf) 26:481-512
3. Pereira AM, van Thiel SW, Lindner JR, Roelfsema F, van der Wall EE, Morreau H, Smit JW, Romijn JA, Bax JJ 2004 Increased prevalence of regurgitant valvular heart disease in acromegaly. J Clin Endocrinol Metab 89:71-75
4. Colao A, Spinelli L, Marzullo P, Pivonello R, Petretta M, Di Somma C, Vitale G, Bonaduce D, Lombardi G 2003 High prevalence of cardiac valve disease in acromegaly: an observational, analytical, case-control study. J Clin Endocrinol Metab 88:3196-3201
5. Colao A, Cuocolo A, Marzullo P, Nicolai E, Ferone D, Delia Morte AM, Pivonello R, Salvatore M, Lombardi G 2001 Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor 1 levels on cardiac performance. J Clin Endocrinol Metab 86:1551-1557
6. Ezzat S, Forster MJ, Berchtold P, Redelmeier DA, Boerlin V, Harris AG 1994 Acromegaly. Clinical and biochemical features in 500 patients. Medicine (Baltimore) 73:233-240
7. Molitch ME 1992 Clinical manifestations of acromegaly. Endocrinol Metab Clin North Am 21:597-614
8. Podgorski M, Robinson B, Weissberger A, Stiel J, Wang S, Brooks PM 1988 Articular manifestations of acromegaly. Aust NZJ Med 18:28-35
9. Layton MW, Fudman EJ, Barkan A, Braunstein EM, Fox IH 1988 Acromegalic arlhropathy. Characteristics and response to therapy. Arthritis Rheum 31:1022-1027
10. Bates AS, Van't Hoff W, Jones JM, Clayton RN 1993 An audit of outcome of treatment in acromegaly. Q J Med 86:293-299
11. Orme SM, McNally RJ, Cartwright RA, Belchetz PE 1998 Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 83:2730-2734
12. Swearingen B, Barker FG, Katznelson L, Biller BM, Grinspoon S, Klibanski A, Moayeri N, Black PM, Zervas NT 1998 Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 83:3419-3426
13. Webb SM, Prieto L, Badia X, Albareda M, Catala M, Gaztambide S, Lucas T, Paramo C, Pico A, Lucas A, Halperin I, Obiols G, Astorga R 2002 Acromegaly Quality of Life Questionnaire (ACROQOL) a new health-related quality of life questionnaire for patients with acromegaly: development and psychometric properties. Clin Endocrinol (Oxf) 57:251-258
14. Beauregard C, Truong U, Hardy J, Serri O 2003 Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clin Endocrinol (Oxf) 58:86-91
15. Holdaway IM, Rajasoorya RC, Gamble GD 2004 Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 89:667-674
16. Biermasz NR, van Dulken H, Roelfsema F 2000 Ten-year follow-up results of transsphenoidal microsurgery in acromegaly. J Clin Endocrinol Metab 85:4596-4602
17. Lancranjan I, Atkinson AB 1999 Results of a European multicentre study with Sandostatin LAR in acromegalic patients. Sandostatin LAR Group. Pituitary 1:105-114
18. Cozzi R, Attanasio R, Montini M, Pagani G, Lasio G, Lodrini S, Barausse M, Albizzi M, Dallabonzana D, Pedroncelli AM 2003 Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results? J Clin Endocrinol Metab 88:3090-3098
19. Biermasz NR, Dekker FW, Pereira AM, Van Thiel SW, Schutte PJ, van Dulken H, Romijn JA, Roelfsema F 2004 Determinants of survival in treated acromegaly in a single center: predictive value of serial insulin-like growth factor I measurements. J Clin Endocrinol Metab 89:2789-2796
20. van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML, Freda PU, Stewart PM, Friend KE, Clemmons DR, Johannsson G, Stavrou S, Cook DM, Phillips LS, Strasburger CJ, Hackett S, Zib KA, Davis RJ, Scarlett JA, Thorner MO 2001 Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 358:1754-1759
21. Colao A, Ferone D, Marzullo P, Lombardi G 2004 Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 25:102-152
22. Biermasz NR, Thiel van SW, Pereira AM, Hoftijzer HC, Hemert van AM, Smit JW, Romijn JA, Roelfsema F 2004 Decreased quality of life in patients with acromegaly despite long-term cure of GH excess. J Clin Endocrinol Metab 89:5369-5376
23. World Health Organization 1999 Definition, diagnosis and classification of diabetes mellitus: report of a WHO consultation. Publication WHO/NCD/NCS/99.2.1999. Geneva: World Health Organization
24. Ware Jr JE, Sherbourne CD 1992 The MOS 36-item short-form health survey (SF-36). 1. Conceptual framework and item selection. Med Care 30:473-483
25. Brazier JE, Harper R, Jones NM, O'Cathain A, Thomas KJ, Usherwood T, Westlake L 1992 Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ 305:160-164
26. van der Zee KI, Sanderman R, Heyink J 1996 A comparison of two multidimensional measures of health status: the Nottingham Health Profile and the RAND 36-Item Health Survey 1.0. Qual Life Res 5:165-174
27. Van der Zee KI, Sanderman R 1992 Het meten van de algemene gezondheidstoestand met de RAND-36, een handleiding. Groningen, Nederland: Noordelijk Centrum voor Gezondheidsvraagstukken
28. Hunt SM, McKenna SP, McEwen J, Backett EM, Williams J, Papp E 1980 A quantitative approach to perceived health status: a validation study. J Epidemiol Community Health 34:281-286
29. Hunt SM, McEwen J 1980 The development of a subjective health indicator. Sociol Health Illn 2:231-246
30. Hinz A, Klaiberg A, Schumacher J, Brahler E 2003 [The psychometric quality of the Nottingham Health Profile (NHP) in the general population]. Psychother Psychosom Med Psychol 53:353-358 (German)
31. Smets EM, Garssen B, Bonke B, De Haes JC 1995 The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res 39:315-325
32. Smets EM, Visser MR, Willems-Groot AF, Garssen B, Schuster-Uitterhoeve AL, De Haes JC 1998 Fatigue and radiotherapy: (B) experience in patients 9 months following treatment. Br J Cancer 78:907-912
33. Zigmond AS, Snaith RP 1983 The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 67:361-370
34. Spinhoven P, Ormel J, Sloekers PP, Kempen GI, Speckens AE, Van Hemert AM 1997 A validation study of the Hospital Anxiety and Depression Scale (HADS) in different groups of Dutch subjects. Psychol Med 27:363-370
35. Watt T, Groenvold M, Bjorner JB, Noerholm V, Rasmussen NA, Bech P 2000 Fatigue in the Danish general population. Influence of sociodemographic factors and disease. J Epidemiol Community Health 54:827-833
36. van den Berg G, Pincus SM, Frolich M, Veldhuis JD, Roelfsema F 1998 Reduced disorderliness of growth hormone release in biochemically inactive acromegaly after pituitary surgery. Eur J Endocrinol 138:164-169
37. Janssen YJ, Frolich M, Roelfsema F 1997 A low starting dose of genotropin in growth hormone-deficient adults. J Clin Endocrinol Metab 82:129-135
38. Picavet HSJ, Hazes JMW 2003 Prevalence of self reported musculoskeletal diseases is high. Ann Rheum Dis 62:644-650
39. Schelleman H, Klungel OH, Kromhout D, de Boer A, Stricker BH, Verschuren WM 2004 Prevalence and determinants of undertreatment of hypertension in the Netherlands. J Hum Hypertens 18:317-324
40. Mooy JM, Grootenhuis PA, de Vries H, Valkenburg HA, Bouter LM, Kostense PJ, Heine RJ 1995 Prevalence and determinants of glucose intolerance in a Dutch Caucasian population. The Hoorn Study. Diabetes Care 18:1270-1273
41. van Rossum CTM, van de Mheen H, Witteman JCM, Hofman A, Mackenbach JP, Grobbee DE 2000 Prevalence, treatment, and control of hypertension by sociodemographic factors among the Dutch elderly. Hypertension 35:814-821
42. Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, von Werder K, Melmed S 2000 Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 85:526-529
43. 2004 Biochemical assessment and long-term monitoring in patients with acromegaly: statement from a joint consensus conference of The Growth Hormone Research Society and The Pituitary Society. J Clin Endocrinol Metab 89:3099-3102
44. Melmed S, Casanueva FF, Cavagnini F, Chanson P, Frohman L, Grossman A, Ho K, Kleinberg D, Lamberts S, Laws E, Lombardi G, Vance ML, Werder KV, Wass J, Giustina A 2002 Guidelines for acromegaly management. J Clin Endocrinol Metab 87:4054-4058
45. Serri O, Beauregard C, Hardy J 2004 Long-term biochemical status and disease-related morbidity in 53 postoperative patients with acromegaly. J Clin Endocrinol Metab 89:658-661
46. van Manen JG, Bindels PJ, Dekker FW, Bottema BJ, van der Zee JS, Ijzermans CJ, Schade E 2003 The influence of COPD on health-related quality of life independent of the influence of comorbidity. J Clin Epidemiol 56:1177-1184
47. Picavet HSJ, Hoeymans N 2004 Health related quality of life in multiple musculoskeletal diseases: SF-36 and EQ-5D in the DMC3 study. Ann Rheum Dis 63:723-729
48. Dons RF, Rosselet P, Pastakia B, Doppman J, Gorden P 1988 Arthropathy in acromegalic patients before and after treatment: a long-term follow-up study. Clin Endocrinol (Oxf) 28:515-524
49. Bluestone R, Bywaters E, Hartog M, Holt PJL, Hyde S 1971 Acromegalic arthropathy. Ann Rheum Dis 30:243-258
50. Erdheim J 1931 Uber Wirbelsaulenveranderungen bei Akromegalie. Arch Pathol Anat Physiol Klin Med 281:197
51. Colao A, Marzullo P, Vallone G, Marino V, Annecchino M, Ferone D, De Brasi D, Scarpa R, Oriente P, Lombardi G 1998 Reversibility of joint thickening in acromegalic patients: an ultrasonography study. J Clin Endocrinol Metab 83:2121-2125
52. Colao A, Cannavo S, Marzullo P, Pivonello R, Squadrito S, Vallone G, Almoto B, Bichisao E, Trimarchi F, Lombardi G 2003 Twelve months of treatment with octreotide-LAR reduces joint thickness in acromegaly. Eur J Endocrinol 148:31-38